AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

Core Insights - AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for various therapeutic indications [1][3] - The company will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on May 21, 2025 [1] Company Overview - AEON is developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, for debilitating medical conditions [3] - ABP-450 is the same botulinum toxin complex marketed for cosmetic uses under the name Jeuveau by Evolus [3] - The product is manufactured by Daewoong in compliance with current Good Manufacturing Practice (cGMP) and is approved by the U.S. FDA, Health Canada, and the European Medicines Agency [3] - ABP-450 is approved as a biosimilar in Mexico and India [3] - AEON holds exclusive development and distribution rights for therapeutic indications of ABP-450 in the U.S., Canada, EU, UK, and other international territories [3] - The company has a highly experienced management team with expertise in biopharmaceutical and botulinum toxin development and commercialization [3]